iScience · 2021 · 10 citations · 55 references
Life SciencesMolecular BiologyOncologyCell SignalingGenome EditingMolecular OncologyCancer BiomarkersCrispr-cas SystemsMtor Inhibitor TherapySignal Transduction In CancerBromodomain InhibitionBromodomain ProteinsCrispr-cas9 Genome EditingEarly-phase Clinical TrialsGenome-wide Crispr ScreeningIndication AppropriatenessManganese Transport ProteinsManganese-binding Proteins
BET bromodomain inhibitors hold promise as therapeutic agents in diverse indications, but their clinical progression has been challenging and none have received regulatory approval. Early clinical trials in cancer have shown heterogeneous clinical responses, development of resistance, and adverse events. Increased understanding of their mechanism(s) of action and identification of biomarkers are needed to identify appropriate indication(s) and achieve efficacious dosing. Using genome-wide CRISPR-Cas9 screens at different concentrations, we report molecular mechanisms defining cellular responses to BET inhibitors, some of which appear specific to a single compound concentration. We identify multiple transcriptional regulators and mTOR pathway members as key determinants of JQ1 sensitivity and two Ca 2+ /Mn 2+ transporters, ATP2C1 and TMEM165, as key determinants of JQ1 resistance. Our study reveals new molecular mediators of BET bromodomain inhibitor effects, suggests the involvement of manganese, and provides a rich resource for discovery of biomarkers and targets for combination therapies.
55
Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
Ophir Shalem, Neville E. Sanjana, Ella Hartenian et al. · Science · 2013 · 5.5K citations · Full text
Selective inhibition of BET bromodomains
P. Filippakopoulos, Jun Qi, S. Picaud et al. · Nature · 2010 · 4.3K citations · Full text
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake Delmore, Ghayas C. Issa, Madeleine E. Lemieux et al. · Cell · 2011 · 2.8K citations · Full text